Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 10/20 | 0.43 |
| ▸ | PGR | P06401 | 8/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2390300 | 0.90 | NR3C1 (0.50) | NR3C1PGRTDP1ALDH1A1CYP3A4 | |
| SCHEMBL2389909 | 0.82 | PGR (0.42) | NR3C1PGRAR | |
| SCHEMBL2393569 | 0.82 | PGR (0.45) | NR3C1PGRTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL2395174 | 0.80 | PGR (0.43) | NR3C1PGRTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL2397569 | 0.79 | PGR (0.45) | NR3C1PGRTDP1ALDH1A1CYP3A4 | |
| SCHEMBL2393170 | 0.78 | NPC1 (0.44) | NR3C1PGRALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2389906 | 0.76 | PGR (0.44) | NR3C1PGRAR | |
| SCHEMBL2395912 | 0.76 | KDM4E (0.46) | PGRTDP1ALDH1A1L3MBTL1HSD17B10 | |
| SCHEMBL2395158 | 0.75 | PGR (0.45) | NR3C1PGRTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL2393220 | 0.74 | PGR (0.46) | NR3C1PGRTDP1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017775-B2 | 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20090326009-A1 | Novel 1-2-Dihydroquinoline Derivative Having Glucocorticoid Receptor Binding Activity | Santen Pharmaceutical Co., (JP) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326009-A1 | Novel 1-2-Dihydroquinoline Derivative Having Glucocorticoid Receptor Binding Activity | NR3C1, NR3C2, NR5A1 | NR3C1 1/4885PGR 201/4885TDP1 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.